Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antifungal Agents | 5 | 2024 | 305 | 1.370 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 294 | 1.270 |
Why?
|
| Bacteremia | 2 | 2019 | 429 | 0.910 |
Why?
|
| Candida tropicalis | 1 | 2024 | 17 | 0.900 |
Why?
|
| Candidiasis, Invasive | 1 | 2024 | 23 | 0.880 |
Why?
|
| Candidemia | 3 | 2015 | 43 | 0.840 |
Why?
|
| Anti-Bacterial Agents | 7 | 2022 | 2575 | 0.820 |
Why?
|
| Vancomycin | 3 | 2022 | 236 | 0.810 |
Why?
|
| Mycoses | 2 | 2021 | 117 | 0.780 |
Why?
|
| Mastoiditis | 1 | 2022 | 33 | 0.750 |
Why?
|
| Rat-Bite Fever | 1 | 2021 | 4 | 0.740 |
Why?
|
| Streptobacillus | 1 | 2021 | 4 | 0.740 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2021 | 3 | 0.740 |
Why?
|
| Autoimmune Hypophysitis | 1 | 2021 | 5 | 0.740 |
Why?
|
| Skin Diseases | 1 | 2022 | 136 | 0.700 |
Why?
|
| Near Drowning | 1 | 2021 | 26 | 0.690 |
Why?
|
| Procyonidae | 1 | 2020 | 1 | 0.680 |
Why?
|
| Bites and Stings | 1 | 2020 | 27 | 0.670 |
Why?
|
| Drowning | 1 | 2021 | 47 | 0.660 |
Why?
|
| Cellulitis | 1 | 2020 | 63 | 0.660 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 230 | 0.640 |
Why?
|
| Salmonella Infections | 1 | 2019 | 32 | 0.640 |
Why?
|
| Hand | 1 | 2020 | 107 | 0.630 |
Why?
|
| Abscess | 1 | 2020 | 140 | 0.610 |
Why?
|
| Photorhabdus | 1 | 2018 | 2 | 0.600 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2018 | 23 | 0.580 |
Why?
|
| Disease Management | 2 | 2021 | 565 | 0.580 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 276 | 0.570 |
Why?
|
| Neonatal Sepsis | 1 | 2018 | 40 | 0.560 |
Why?
|
| Child | 16 | 2024 | 25868 | 0.440 |
Why?
|
| Amphotericin B | 2 | 2022 | 91 | 0.430 |
Why?
|
| Infant | 10 | 2024 | 13243 | 0.420 |
Why?
|
| Child, Preschool | 11 | 2024 | 14873 | 0.410 |
Why?
|
| Retrospective Studies | 10 | 2024 | 17568 | 0.380 |
Why?
|
| Adolescent | 12 | 2025 | 20573 | 0.350 |
Why?
|
| Candida | 1 | 2011 | 84 | 0.340 |
Why?
|
| Bartonella | 1 | 2010 | 10 | 0.340 |
Why?
|
| Bartonella Infections | 1 | 2010 | 7 | 0.340 |
Why?
|
| Retinitis | 1 | 2010 | 18 | 0.330 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2024 | 835 | 0.300 |
Why?
|
| Female | 17 | 2024 | 71503 | 0.280 |
Why?
|
| Humans | 23 | 2025 | 133373 | 0.280 |
Why?
|
| Male | 14 | 2024 | 65592 | 0.240 |
Why?
|
| Orf virus | 1 | 2025 | 4 | 0.240 |
Why?
|
| Ecthyma, Contagious | 1 | 2025 | 5 | 0.240 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8632 | 0.230 |
Why?
|
| Drug Resistance, Fungal | 1 | 2024 | 30 | 0.230 |
Why?
|
| Soft Tissue Infections | 1 | 2025 | 91 | 0.220 |
Why?
|
| Cough | 1 | 2023 | 96 | 0.200 |
Why?
|
| Pleural Effusion | 1 | 2023 | 109 | 0.200 |
Why?
|
| Phaeohyphomycosis | 1 | 2022 | 10 | 0.200 |
Why?
|
| Cerebral Ventriculitis | 1 | 2022 | 16 | 0.190 |
Why?
|
| Central Nervous System Infections | 1 | 2022 | 22 | 0.190 |
Why?
|
| Incidence | 2 | 2024 | 3395 | 0.180 |
Why?
|
| Cephalosporins | 1 | 2022 | 143 | 0.180 |
Why?
|
| Arthritis, Infectious | 1 | 2021 | 67 | 0.170 |
Why?
|
| Exanthema | 1 | 2021 | 71 | 0.170 |
Why?
|
| Aggregatibacter actinomycetemcomitans | 1 | 2020 | 4 | 0.170 |
Why?
|
| Pets | 1 | 2020 | 18 | 0.170 |
Why?
|
| Fusobacterium nucleatum | 1 | 2020 | 25 | 0.170 |
Why?
|
| Risk Factors | 4 | 2024 | 10954 | 0.160 |
Why?
|
| Clinical Clerkship | 1 | 2020 | 87 | 0.160 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 748 | 0.160 |
Why?
|
| Fever | 1 | 2021 | 312 | 0.150 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 162 | 0.150 |
Why?
|
| Acute Disease | 1 | 2022 | 1184 | 0.150 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2020 | 158 | 0.150 |
Why?
|
| Area Under Curve | 1 | 2019 | 330 | 0.140 |
Why?
|
| Ceftazidime | 1 | 2018 | 50 | 0.140 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 107 | 0.140 |
Why?
|
| HIV Infections | 1 | 2010 | 2076 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2021 | 542 | 0.130 |
Why?
|
| Rhinitis | 1 | 2017 | 38 | 0.130 |
Why?
|
| Sinusitis | 1 | 2017 | 114 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 562 | 0.120 |
Why?
|
| Students, Medical | 1 | 2020 | 363 | 0.120 |
Why?
|
| Ambulatory Care | 1 | 2018 | 415 | 0.120 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2018 | 485 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2018 | 409 | 0.120 |
Why?
|
| Rats | 1 | 2021 | 3851 | 0.110 |
Why?
|
| Body Weight | 1 | 2019 | 1035 | 0.110 |
Why?
|
| Algorithms | 1 | 2021 | 1730 | 0.110 |
Why?
|
| Hypokalemia | 1 | 2012 | 41 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 319 | 0.090 |
Why?
|
| Animals | 3 | 2025 | 36222 | 0.090 |
Why?
|
| Kidney | 1 | 2018 | 1395 | 0.090 |
Why?
|
| Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2010 | 2 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 706 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2019 | 13103 | 0.080 |
Why?
|
| Organophosphonates | 1 | 2010 | 21 | 0.080 |
Why?
|
| Oxazines | 1 | 2010 | 26 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1033 | 0.080 |
Why?
|
| Age Distribution | 1 | 2011 | 427 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2010 | 84 | 0.080 |
Why?
|
| Texas | 2 | 2025 | 3666 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3869 | 0.080 |
Why?
|
| Doxycycline | 1 | 2010 | 121 | 0.080 |
Why?
|
| Adenine | 1 | 2010 | 123 | 0.080 |
Why?
|
| Rifampin | 1 | 2010 | 136 | 0.080 |
Why?
|
| Lung | 2 | 2023 | 1571 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 284 | 0.080 |
Why?
|
| Time Factors | 1 | 2019 | 6544 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2015 | 3418 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2012 | 494 | 0.070 |
Why?
|
| Anti-HIV Agents | 1 | 2010 | 350 | 0.070 |
Why?
|
| Biopsy | 1 | 2010 | 1204 | 0.060 |
Why?
|
| Goats | 1 | 2025 | 60 | 0.060 |
Why?
|
| Sheep | 1 | 2025 | 232 | 0.060 |
Why?
|
| Neoplasms | 1 | 2018 | 2992 | 0.050 |
Why?
|
| Ascomycota | 1 | 2022 | 26 | 0.050 |
Why?
|
| Dyspnea | 1 | 2023 | 160 | 0.050 |
Why?
|
| Skin | 1 | 2025 | 542 | 0.050 |
Why?
|
| Young Adult | 2 | 2017 | 9923 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2022 | 285 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 639 | 0.040 |
Why?
|
| Nafcillin | 1 | 2018 | 14 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 1013 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 15 | 0.040 |
Why?
|
| Clindamycin | 1 | 2018 | 42 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 1353 | 0.040 |
Why?
|
| Acetazolamide | 1 | 2018 | 32 | 0.040 |
Why?
|
| Learning | 1 | 2020 | 375 | 0.030 |
Why?
|
| Debridement | 1 | 2017 | 92 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 679 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 501 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 2205 | 0.030 |
Why?
|
| Endoscopy | 1 | 2017 | 280 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1864 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 549 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1100 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 2207 | 0.020 |
Why?
|
| Parents | 1 | 2018 | 1073 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 3988 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2006 | 33 | 0.020 |
Why?
|
| Camptothecin | 1 | 2006 | 79 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2006 | 250 | 0.010 |
Why?
|
| Middle Aged | 2 | 2018 | 28985 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 745 | 0.010 |
Why?
|
| Adult | 2 | 2018 | 31684 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 1584 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1714 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 1364 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 5443 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2006 | 3718 | 0.010 |
Why?
|
| Aged | 1 | 2006 | 21500 | 0.000 |
Why?
|